Role of SCD40L in the Prediction of Super-response to Cardiac Resynchronization Therapy

Overview

Journal An Sist Sanit Navar

Specialty General Medicine

Date 2021 Jun 16

PMID 34132247

Authors

C Pujol

N Varo Cenarruzabeitia

M Rodriguez Manero

J Barba

S Castano Rodriguez

A Macias Gallego

M J Torres

I Garcia Bolao

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this paper is to analyze the role of the biomarkers Interleukin 6, Tumoral Necrosis Factor a, sCD40L, high sensitive Troponin T, high sensitive C-Reactive Protein and Galectin-3 in predicting super response (SR) to Cardiac Resynchronization Therapy (CRT), as they have not been studied in this field before.

Methods: Clinical, electrocardiographic and echocardiographic data was obtained preimplant and after one year. SR was defined as reduction in LVESV = 30% at one year follow-up. Blood samples were extracted preimplant. Multivariate logistic regression and ROC curves were performed.

Results: 50 patients were included, 23 (46%) were SR. Characteristics related to SR were: female (35 vs. 11%, p?=?0.04), suffering from less ischemic cardiomyopathy (13 vs. 63%, p?<?0.0001) and lateral (0 vs. 18%, p?=?0.03), inferior (4 vs. 33%, p?=?0.01) and posterior infarction (0 vs. 22%, p?=?0.01); absence of mitral regurgitation (47% vs. 22%, p?=?0.04), wider QRS width (157.7?±?22.9 vs. 140.8?±?19.2ms, p?=?0.01), higher concentrations of sCD40L (6.9?±?5.1 vs. 4.4?±?3.3 ng/mL, p?=?0.02), and left ventricular lead more frequent in lateral medial position (69 vs. 26%, p?=?0.002). QRS width, lateral medial position of the lead and absence of mitral regurgitation were independent predictors of SR. sCD40L showed a moderate direct correla-tion with SR (r?=?0.39, p?=?0.02) and with the reduction of LVESV (r?=?0.44, p?=?0.02).

Conclusions: sCD40L correlates significantly with SR to CRT. QRS width, absence of mitral regurgitation and lateral medial position of the lead are independent predictors of SR in this cohort.

References

Chung E, Leon A, Tavazzi L, Sun J, Nihoyannopoulos P, Merlino J . Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation. 2008; 117(20):2608-16. DOI: 10.1161/CIRCULATIONAHA.107.743120. View

Blanc J, Fatemi M, Bertault V, Baraket F, Etienne Y . Evaluation of left bundle branch block as a reversible cause of non-ischaemic dilated cardiomyopathy with severe heart failure. A new concept of left ventricular dyssynchrony-induced cardiomyopathy. Europace. 2005; 7(6):604-10. DOI: 10.1016/j.eupc.2005.06.005. View

Linde C, Abraham W, Gold M, St John Sutton M, Ghio S, Daubert C . Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008; 52(23):1834-1843. DOI: 10.1016/j.jacc.2008.08.027. View

Arrieta V, Sadaba J, Alvarez V, Rodriguez J, Lopez-Andres N . Galectin-3 as a novel biotarget in cardiovascular alterations associated to development of severe aortic stenosis. An Sist Sanit Navar. 2019; 42(2):199-208. DOI: 10.23938/ASSN.0643. View

Ajmone Marsan N, Breithardt O, Delgado V, Bertini M, Tops L . Predicting response to CRT. The value of two- and three-dimensional echocardiography. Europace. 2008; 10 Suppl 3:iii73-9. DOI: 10.1093/europace/eun219. View

Desideri G, Cipollone F, Valeri L, Grassi D, Necozione S, Croce G . Enhanced plasma soluble CD40 ligand levels in essential hypertensive patients with blunted nocturnal blood pressure decrease. Am J Hypertens. 2007; 20(1):70-6. DOI: 10.1016/j.amjhyper.2006.06.007. View

Gremmel T, Frelinger 3rd A, Michelson A . Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. PLoS One. 2015; 10(8):e0134599. PMC: 4523196. DOI: 10.1371/journal.pone.0134599. View

Chung I, Choudhury A, Patel J, Lip G . Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: relationship to platelet volume, mass and granularity. J Intern Med. 2007; 263(3):313-21. DOI: 10.1111/j.1365-2796.2007.01891.x. View

Ypenburg C, van Bommel R, Borleffs C, Bleeker G, Boersma E, Schalij M . Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol. 2009; 53(6):483-90. DOI: 10.1016/j.jacc.2008.10.032. View

10.

Jin H, Yang S, Hua W, Gu M, Niu H, Ding L . Significant mitral regurgitation as a predictor of long-term prognosis in patients receiving cardiac resynchronisation therapy. Kardiol Pol. 2018; 76(6):987-992. DOI: 10.5603/KP.a2018.0035. View

11.

Senchenkova E, Russell J, Vital S, Yildirim A, Orr A, Granger D . A critical role for both CD40 and VLA5 in angiotensin II-mediated thrombosis and inflammation. FASEB J. 2018; 32(6):3448-3456. DOI: 10.1096/fj.201701068R. View

12.

Ueland T, Aukrust P, Yndestad A, Otterdal K, Froland S, Dickstein K . Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J. 2005; 26(11):1101-7. DOI: 10.1093/eurheartj/ehi132. View

13.

van der Heijden A, Hoke U, Thijssen J, Borleffs C, van Rees J, van der Velde E . Super-responders to cardiac resynchronization therapy remain at risk for ventricular arrhythmias and benefit from defibrillator treatment. Eur J Heart Fail. 2014; 16(10):1104-11. DOI: 10.1002/ejhf.152. View

14.

van der Heijden A, Hoke U, Thijssen J, Borleffs C, Wolterbeek R, Schalij M . Long-Term Echocardiographic Outcome in Super-Responders to Cardiac Resynchronization Therapy and the Association With Mortality and Defibrillator Therapy. Am J Cardiol. 2016; 118(8):1217-1224. DOI: 10.1016/j.amjcard.2016.07.041. View

15.

Bax J, Abraham T, Barold S, Breithardt O, Fung J, Garrigue S . Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol. 2005; 46(12):2153-67. DOI: 10.1016/j.jacc.2005.09.019. View

16.

Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M . Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002; 106(4):399-402. DOI: 10.1161/01.cir.0000025419.95769.f0. View

17.

Cipriani M, Lunati M, Landolina M, Proclemer A, Boriani G, Ricci R . Prognostic implications of mitral regurgitation in patients after cardiac resynchronization therapy. Eur J Heart Fail. 2016; 18(8):1060-8. DOI: 10.1002/ejhf.569. View

18.

van Bommel R, Bax J, Abraham W, Chung E, Pires L, Tavazzi L . Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis. Eur Heart J. 2009; 30(20):2470-7. DOI: 10.1093/eurheartj/ehp368. View

19.

Hsu J, Solomon S, Bourgoun M, McNitt S, Goldenberg I, Klein H . Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol. 2012; 59(25):2366-73. DOI: 10.1016/j.jacc.2012.01.065. View

20.

Kojok K, Mohsen M, El Kadiry A, Mourad W, Merhi Y . Aspirin Reduces the Potentiating Effect of CD40L on Platelet Aggregation via Inhibition of Myosin Light Chain. J Am Heart Assoc. 2020; 9(3):e013396. PMC: 7033871. DOI: 10.1161/JAHA.119.013396. View